RenovoRx Corporation (RNXT) Enterprise Value to EBITDA Ratio

Graphic logo of RenovoRx, Inc. (RNXT)

The price chart for RenovoRx, Inc. (RNXT) demonstrates an EV/EBITDA of 0.00. RenovoCath intellectual property protection and support from influential oncology entities limit new market entrants, despite strict FDA oversight. Personnel policy relies on attracting specialized engineers and physicians through a stock option system. Business development is based on implementing local therapy in clinics to reduce treatment toxicity.

RNXT RenovoRx Corp: Company Value to EBITDA in the range 11/23/2025 - 11/14/2026

Metric breakdowns and analytics for renovorx.com (RNXT)

- market price and analyst price targets:
Price Chart RenovoRx Corp|RNXT - Analyst Median Target
- market capitalization details:
Market Valuation RenovoRx Corporation|RNXT - Aggregate Business Value
- business book valuation details:
Net Assets per Single Share RenovoRx|RNXT - Total Stockholders' Equity|Market Value to Book Value Ratio renovorx.com|RNXT - Cumulative Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital RenovoRx, Inc.|RNXT - Long-Term Debt to Capital|Short-Term Debt to Capital RenovoRx|RNXT - Company Total Debt|Debts to Book Capitalization RenovoRx Corporation|RNXT - Company Long-Term Loans and Borrowings|Company Short-Term Debt RenovoRx|Quick Ratio renovorx.com
- business earnings and investment ratios data:
RNXT - Company Net Income|Expected Profit RenovoRx, Inc.|RNXT - Price to Earnings Multiple|Future Price to Earnings RenovoRx, Inc.|RNXT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio RenovoRx Corporation|RNXT - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months RenovoRx|RNXT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months renovorx.com|RNXT - Earnings per share increase in current year|Expected earnings per share growth for next year RenovoRx, Inc.
- revenue and sales details:
RNXT - Company Sales Volume|Company Future Sales Volume RenovoRx Corp|RNXT - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple RenovoRx Corporation
Analysis of all company metrics:RenovoRx Corp RNXT
Product sample of renovorx.com

Since the development of pancreatic cancer therapy is independent of macroeconomic cycles, the value of RenovoRx, Inc. (RNXT) is driven by clinical success rather than market conditions. The company's EV/EBITDA ratio relates the total enterprise value, including debt, to operating profit before taxes, allowing investors to distinguish fundamental asset undervaluation from critical leverage risks by analyzing the trends on this chart.

Key competitors

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TriSalus Life Sciences Inc TLSI|Total Company Value to Operating Income Before Depreciation Ratio PharmaCyte Biotech Inc. (PMCB)